Supplement Support Designed for Active Cancer Treatment
OncoCare formulations are built around your specific chemotherapy protocol , interaction-aware, evidence-based, and vetted by oncology research.
Formulated for ovarian cancer and HER2+ breast cancer patients in active treatment
Cancer patients take supplements during treatment
Products formulated for chemo compatibility
ELAHERE + ENHERTU , ADC-specific formulations
Evidence-based ingredients with OC and breast cancer data
Every OncoCare product is manufactured in US-based cGMP certified facilities, third-party tested for identity and potency, and formulated with premium branded ingredients — no fillers, no proprietary blends, no shortcuts.
Most supplements aren't formulated for chemotherapy
Hidden Interactions
Many common supplements interfere with ADC therapy through CYP3A4 pathway interactions.
No Oncology Standard
General wellness brands aren't designed for patients in active treatment. Dosing and timing aren't optimized.
Patients Left Guessing
68% of cancer patients take supplements without clinical guidance. Oncologists rarely have time to advise.
Interaction-Aware
Every ingredient passes what we call the Checkpoint Test , evaluated against your drug's CYP3A4 enzyme pathway before it enters any OncoCare formula. Your chemo works the way your oncologist designed it. Your supplements work without getting in the way.
Learn how we vet every ingredient →Protocol-Specific
We formulate for ELAHERE and ENHERTU , not general wellness. Your drug. Your protocol.
Evidence-Based Dosing
Doses drawn from peer-reviewed ovarian and breast cancer clinical studies, not supplement convention.
Our Story
Born from a real patient's journey at MD Anderson
OncoCare didn't start in a lab or a boardroom. It started in a hospital waiting room at MD Anderson Cancer Center in Houston, Texas, where a husband was doing everything he could to help his wife through stage IV ovarian cancer.
Navigating supplement decisions in real time, cross-referencing clinical studies, checking CYP3A4 drug interactions, coordinating with the integrative medicine team, revealed a gap no one had filled: cancer patients in active treatment had no supplement brand built specifically for them. Most products on the market were designed for general wellness, not for someone on an ADC chemotherapy protocol.
So we built one. Every OncoCare formulation starts with the drug, not the supplement shelf. We ask: what does this patient's specific chemotherapy do, what does it deplete, what does it stress, and what does the peer-reviewed literature say can help without interfering? That question drives every ingredient decision we make.
, Fito Kahn, Founder | Austin, Texas
“No cancer patient should have to guess whether their supplements are safe and effective.”
, Fito Kahn, OncoCare Founder
Two protocols. One clinical framework.
ELAHERE Protocol
For ovarian cancer patients on mirvetuximab soravtansine
- AM Protect$49.95
- PM Restore (ELAHERE)$54.95
- AHCC Solo$119.95
Full Protocol Bundle: $194.95 (save $30)
Shop Ovarian ProtocolENHERTU Protocol
For HER2+ breast cancer patients on trastuzumab deruxtecan
- AM Protect$49.95
- PM Restore (ENHERTU)$57.95
- AHCC Solo$119.95
- Nausea + GI Support$39.95
Full Protocol Bundle: $224.95 (save $42)
Shop Breast Protocol